Moxaviv (Moxonidine)

Moxonidine, the active ingredient in Moxaviv, is an imidazoline receptor agonist presented as an oral tablet for oral use. It lowers blood pressure in patients with essential hypertension.

GNH USA supplies Moxaviv as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Moxonidine is used to treat hypertension by modulating central sympathetic activity.

- Essential hypertension: reduces systolic and diastolic blood pressure in adults. - Primary hypertension: helps achieve target blood pressure when lifestyle measures are insufficient. - Elevated blood pressure: contributes to overall cardiovascular risk reduction.

Moxonidine may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Dry mouth: sensation of oral dryness. - Fatigue: feeling of tiredness or lack of energy. - Dizziness: light‑headedness, especially when standing. - Headache: mild to moderate cranial pain. - Nausea: upset stomach with urge to vomit. - Constipation: reduced bowel movements.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure causing fainting. - Bradycardia: unusually slow heart rate. - Allergic reaction: rash, itching, swelling, or difficulty breathing. - Hepatic dysfunction: abnormal liver enzymes or jaundice. - Arrhythmia: irregular heart rhythm. - Syncope: sudden loss of consciousness.

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for potential risks. - Blood pressure monitoring: check regularly to avoid excessive hypotension. - Renal impairment: dose may need adjustment in reduced kidney function. - Elderly patients: start at lower dose and titrate cautiously. - Hepatic disease: avoid use in severe liver dysfunction. - Discontinuation: do not stop abruptly; taper under medical supervision. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Moxonidine can interact with other medicines that affect blood pressure or sympathetic activity.

Major Interactions (Avoid): - MAO inhibitors: risk of profound hypotension. - Clonidine or other central antihypertensives: additive blood‑pressure lowering effect. - Potassium‑sparing diuretics: may enhance hypotensive response.

Moderate Interactions (Monitor Closely):\n- NSAIDs: may blunt antihypertensive effect. - Beta‑blockers: monitor for excessive heart‑rate reduction. - Diuretics: watch for electrolyte disturbances. - Lithium: monitor lithium levels for toxicity. - CYP2D6 inhibitors: may increase plasma concentration of moxonidine.